218 related articles for article (PubMed ID: 20028452)
1. Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant.
Martín-García E; Burokas A; Martín M; Berrendero F; Rubí B; Kiesselbach C; Heyne A; Gispert JD; Millán O; Maldonado R
J Neurochem; 2010 Mar; 112(5):1338-13351. PubMed ID: 20028452
[TBL] [Abstract][Full Text] [Related]
2. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.
Falenski KW; Thorpe AJ; Schlosburg JE; Cravatt BF; Abdullah RA; Smith TH; Selley DE; Lichtman AH; Sim-Selley LJ
Neuropsychopharmacology; 2010 Jul; 35(8):1775-87. PubMed ID: 20357755
[TBL] [Abstract][Full Text] [Related]
3. Residual effects of focal brain ischaemia upon cannabinoid CB(1) receptor density and functionality in female rats.
Rojo ML; Söderström I; Fowler CJ
Brain Res; 2011 Feb; 1373():195-201. PubMed ID: 21145311
[TBL] [Abstract][Full Text] [Related]
4. The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice.
Dodd GT; Mancini G; Lutz B; Luckman SM
J Neurosci; 2010 May; 30(21):7369-76. PubMed ID: 20505104
[TBL] [Abstract][Full Text] [Related]
5. Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats.
Forget B; Barthélémy S; Saurini F; Hamon M; Thiébot MH
Psychopharmacology (Berl); 2006 Nov; 189(1):59-69. PubMed ID: 16969683
[TBL] [Abstract][Full Text] [Related]
6. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid type 1 receptor antagonists for smoking cessation.
Cahill K; Ussher MH
Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD005353. PubMed ID: 21412887
[TBL] [Abstract][Full Text] [Related]
8. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
[TBL] [Abstract][Full Text] [Related]
9. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
10. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.
Cluny NL; Vemuri VK; Chambers AP; Limebeer CL; Bedard H; Wood JT; Lutz B; Zimmer A; Parker LA; Makriyannis A; Sharkey KA
Br J Pharmacol; 2010 Oct; 161(3):629-42. PubMed ID: 20880401
[TBL] [Abstract][Full Text] [Related]
11. Changes in cannabinoid receptor subtype 1 activity and interaction with metabotropic glutamate subtype 5 receptors in the periaqueductal gray-rostral ventromedial medulla pathway in a rodent neuropathic pain model.
Palazzo E; Luongo L; Bellini G; Guida F; Marabese I; Boccella S; Rossi F; Maione S; de Novellis V
CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):148-61. PubMed ID: 22483283
[TBL] [Abstract][Full Text] [Related]
12. Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system.
Pfitzer T; Niederhoffer N; Szabo B
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jan; 371(1):9-17. PubMed ID: 15660243
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
[TBL] [Abstract][Full Text] [Related]
14. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats.
Rubio M; Fernández-Ruiz J; de Miguel R; Maestro B; Michael Walker J; Ramos JA
Neuropharmacology; 2008 May; 54(6):976-88. PubMed ID: 18371990
[TBL] [Abstract][Full Text] [Related]
15. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control.
Son MH; Kim HD; Chae YN; Kim MK; Shin CY; Ahn GJ; Choi SH; Yang EK; Park KJ; Chae HW; Moon HS; Kim SH; Shin YG; Yoon SH
Int J Obes (Lond); 2010 Mar; 34(3):547-56. PubMed ID: 20029379
[TBL] [Abstract][Full Text] [Related]
16. Statistical parametric mapping reveals regional alterations in cannabinoid CB1 receptor distribution and G-protein activation in the 3D reconstructed epileptic rat brain.
Sayers KW; Nguyen PT; Blair RE; Sim-Selley LJ; DeLorenzo RJ
Epilepsia; 2012 May; 53(5):897-907. PubMed ID: 22509801
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
18. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.
Horswill JG; Bali U; Shaaban S; Keily JF; Jeevaratnam P; Babbs AJ; Reynet C; Wong Kai In P
Br J Pharmacol; 2007 Nov; 152(5):805-14. PubMed ID: 17592509
[TBL] [Abstract][Full Text] [Related]
19. Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.
Järbe TU; LeMay BJ; Vemuri VK; Vadivel SK; Zvonok A; Makriyannis A
Psychopharmacology (Berl); 2011 Aug; 216(3):355-65. PubMed ID: 21369753
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats.
Seillier A; Advani T; Cassano T; Hensler JG; Giuffrida A
Int J Neuropsychopharmacol; 2010 Apr; 13(3):373-86. PubMed ID: 19607756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
